Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VALEANT PHARMACEUTICALS INTL INC T.VRX

"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."


TSX:VRX - Post by User

Post by richardtraderon May 16, 2016 3:55pm
71 Views
Post# 24878329

update

update

Short seller Left now long Valeant

 

The hot place down under has officially frozen over. Noted bear Andrew Left of Citron Research fame says he is now long Valeant Pharmaceuticals (VRX+4.7%). He says he "wouldn't be surprised if there is a bounce" in the stock considering the prolonged downtrend. He also points out the importance ofXifaxan (rifaximin), acquired in the Salix deal, which the company expects to be a key growth driver as it looks to lighten its debt load.


<< Previous
Bullboard Posts
Next >>